Patients' demographics and pathological features by race
| White (n=38308) | Black (n=7546) | American Indian/Alaska Native (n=494) | Asian or Pacific Islander (n=7817) | p Value | |
|---|---|---|---|---|---|
| Diagnostic age (years) | 67.14±14.54 | 65.41±14.49 | 62.94±14.51 | 67.62±14.66 | <0.001* |
| Gender, n (%) | |||||
| Male | 23688 (61.8%) | 4195 (56.0%) | 294 (59.5%) | 4375 (56.0%) | <0.001* |
| Female | 14620 (38.2%) | 3351 (44.0%) | 200 (40.5%) | 3442 (44.0%) | |
| Histological classification, n (%) | |||||
| Epithelial tumors | 31512 (82.3%) | 5870 (77.8%) | 422 (85.4%) | 6499 (83.1%) | |
| Adenocarcinoma | 22148 (70.3%) | 4140 (70.5%) | 296 (70.1%) | 4771 (73.4%) | |
| Papillary adenocarcinoma | 62 (0.2%) | 23 (0.4%) | 2 (0.5%) | 7 (0.1%) | |
| Tubular adenocarcinoma | 200 (0.6%) | 37 (0.6%) | 3 (0.7%) | 49 (0.8%) | |
| Mucinous adenocarcinoma | 511 (1.6%) | 117 (2.0%) | 7 (1.7%) | 88 (1.4%) | |
| Signet-ring cell carcinoma | 6484 (20.6%) | 1139 (19.4%) | 88 (20.9%) | 1432 (22.0%) | |
| Adenosquamous carcinoma | 104 (0.3%) | 18 (0.3%) | 1 (0.2%) | 14 (0.2%) | |
| Squamous cell carcinoma | 234 (0.7%) | 78 (1.3%) | 3 (0.7%) | 31 (0.5%) | <0.001* |
| Small cell carcinoma | 60 (0.2%) | 11 (0.2%) | 0 (0.0%) | 9 (0.1%) | |
| Undifferentiated carcinoma | 40 (0.1%) | 6 (0.1%) | 1 (0.2%) | 6 (0.1%) | |
| Carcinoid | 1669 (5.3%) | 301 (5.1%) | 21 (5.0%) | 92 (1.4%) | |
| Non-epithelial tumors | 2007 (5.2%) | 728 (9.6%) | 12 (2.4%) | 402 (5.1%) | |
| Leiomyosarcoma | 38 (1.9%) | 4 (1.0%) | 0 (0.0%) | 4 (1.0%) | |
| GI stromal tumor | 1969 (98.1%) | 724 (99.0%) | 12 (100%) | 398 (99.0%) | |
| Others | 4789 (12.5%) | 948 (12.6%) | 60 (12.1%) | 916 (11.7%) | |
| Grade, n (%)† | <0.001* | ||||
| Grade I | 2106 (7.4%) | 416 (7.7%) | 15 (4.4%) | 328 (5.2%) | |
| Grade II | 7444 (26.4%) | 1542 (28.6%) | 85 (25.1%) | 1505 (23.9%) | |
| Grade III | 18247 (63.8%) | 3269 (60.7%) | 230 (67.8%) | 4326 (68.6%) | |
| Grade IV | 820 (2.9%) | 161 (3.0%) | 9 (2.7%) | 143 (2.3%) | |
| AJCC 7 stage, n (%)‡ | |||||
| 0 | 351 (1.2%) | 63 (1.1%) | 4 (1.0%) | 93 (1.5%) | |
| I | 7880 (26.7%) | 1489 (26.9%) | 104 (25.9%) | 1996 (31.3%) | |
| II | 3765 (12.8%) | 679 (12.3%) | 51 (12.7%) | 780 (12.2%) | <0.001* |
| III | 3497 (11.8%) | 692 (12.5%) | 37 (9.2%) | 876 (13.8%) | |
| IV | 14024 (47.5%) | 2618 (47.2%) | 206 (51.2%) | 2625 (41.2%) | |
| Location, n (%)§ | |||||
| Localized | 10898 (32.0%) | 2205 (33.1%) | 126 (28.5%) | 2394 (34.0%) | |
| Regional | 9048 (26.6%) | 1789 (26.8%) | 116 (26.2%) | 2201 (31.2%) | <0.001* |
| Distant | 14085 (41.4%) | 2669 (40.1%) | 200 (45.2%) | 2449 (34.8%) | |
*Indicates a significant difference among the groups, p<0.05.
†Cell type not determined, not stated or not applicable, n=13,519.
‡Stage unknown or not applicable, n=12335.
§Unstaged—information is not sufficient to assign a stage, n=5985.
AJCC, American Joint Committee on Cancer; GI, gastrointestinal.